duloxetine;
REM sleep;
stage;
2;
sleep;
major depression;
D O I:
10.1016/j.euroneuro.2007.01.006
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Sleep studies in patients with major depression receiving the new selective norepinephrine and serotonin reuptake inhibitor (SNRI) dutoxetine are lacking. Therefore, polysomnography in 10 patients with major depression (7 mates, 39.9 +/- 7.6 years, HAMD-21 score: 23.6 5.6) was recorded twice, before and after 7-14 days of treatment with duloxetine. Stage 3 steep significantly (P<0.01) increased from 21.0 +/- 10.7 to 37.4 +/- 20.1 min. Rapid eye movement (REM) latency significantly (P<0.005) increased from 58.5 +/- 31.1 to 193.6 +/- 72.6 min. REM steep significantly (P<0.005) decreased from 94.8 +/- 34.5 to 51.5 +/- 42.5 min. These results partly differ from those in healthy subjects receiving duloxetine. (c) 2007 Elsevier B.V. and ECNR Alt rights reserved.